Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026. Open the filing →
- Filed
- Jul 9, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001549595-26-000040
FAQ
- What is Nurix Therapeutics, Inc.'s D&A?
- Nurix Therapeutics, Inc. (NRIX) reported D&A of $2.26M in Q1 2026.
- How has Nurix Therapeutics, Inc.'s D&A changed year-over-year?
- Nurix Therapeutics, Inc.'s D&A increased by 0.6% year-over-year, from $2.24M to $2.26M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s D&A?
- Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s D&A has grown at a 34.1% compound annual growth rate (CAGR), from $2.7M to $8.74M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Nurix Therapeutics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude